Axitinib intravitreal implant (Ocular Therapeutix)

阿西替尼玻璃体植入剂 (Ocular Therapeutix)

Report date: 2026/04/08 20:02:35

Base Information

Drug NameAxitinib intravitreal implant (Ocular Therapeutix)

Drug Alias Name阿昔替尼玻璃体植入剂Axitinib intravitreal implantAXPAXLIAXPAXLIOTX-TKI

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonists +[4]

TargetsPlatelet-derived growth factor receptorVascular endothelial growth factor receptor 3Vascular endothelial growth factor receptor 1 +[4]

Therapy Area/IndicationsWet age-related macular degenerationMacular DegenerationDiabetic Retinopathy

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto RicoAustralia +[4]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesOcular Therapeutix Inc

China Registration ClassN/A

Develop Information

Active CompaniesOcular Therapeutix Inc

Inactive CompaniesN/A

Active IndicationsWet age-related macular degenerationMacular DegenerationDiabetic Retinopathy

Inactive IndicationsN/A

Other Information

ATC CodeL01EK01